Free Trial

Palvella Therapeutics (PVLA) Competitors

Palvella Therapeutics logo
$71.30 -2.02 (-2.76%)
As of 04:00 PM Eastern

PVLA vs. QURE, GMTX, XENE, SRRK, RARE, AMRX, IMVT, CNTA, TARS, and APLS

Should you be buying Palvella Therapeutics stock or one of its competitors? The main competitors of Palvella Therapeutics include uniQure (QURE), Gemini Therapeutics (GMTX), Xenon Pharmaceuticals (XENE), Scholar Rock (SRRK), Ultragenyx Pharmaceutical (RARE), Amneal Pharmaceuticals (AMRX), Immunovant (IMVT), Centessa Pharmaceuticals (CNTA), Tarsus Pharmaceuticals (TARS), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry.

Palvella Therapeutics vs. Its Competitors

uniQure (NASDAQ:QURE) and Palvella Therapeutics (NASDAQ:PVLA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

78.8% of uniQure shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 4.8% of uniQure shares are held by insiders. Comparatively, 20.5% of Palvella Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Palvella Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,387.98%. Palvella Therapeutics' return on equity of -62.30% beat uniQure's return on equity.

Company Net Margins Return on Equity Return on Assets
uniQure-1,387.98% -1,010.74% -33.27%
Palvella Therapeutics N/A -62.30%-43.34%

Palvella Therapeutics has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
uniQure$27.12M120.04-$239.56M-$3.92-15.14
Palvella Therapeutics$42.81M18.42-$17.43M-$12.10-5.89

In the previous week, Palvella Therapeutics had 2 more articles in the media than uniQure. MarketBeat recorded 2 mentions for Palvella Therapeutics and 0 mentions for uniQure. Palvella Therapeutics' average media sentiment score of 0.24 beat uniQure's score of 0.00 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
uniQure Neutral
Palvella Therapeutics Neutral

uniQure has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of -0.13, suggesting that its stock price is 113% less volatile than the S&P 500.

uniQure currently has a consensus target price of $71.75, suggesting a potential upside of 20.93%. Palvella Therapeutics has a consensus target price of $75.50, suggesting a potential upside of 5.89%. Given uniQure's higher probable upside, research analysts clearly believe uniQure is more favorable than Palvella Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
uniQure
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83
Palvella Therapeutics
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.92

Summary

Palvella Therapeutics beats uniQure on 9 of the 15 factors compared between the two stocks.

Get Palvella Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PVLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PVLA vs. The Competition

MetricPalvella TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$810.90M$3.44B$6.19B$10.60B
Dividend YieldN/A2.26%5.72%4.86%
P/E RatioN/A8.2221.1124.06
Price / Sales18.42477.59577.46128.87
Price / CashN/A44.5736.5560.64
Price / Book12.7810.3512.076.53
Net Income-$17.43M-$52.53M$3.32B$276.75M
7 Day Performance-2.52%-0.22%-0.16%0.20%
1 Month Performance25.77%10.89%5.76%1.67%
1 Year PerformanceN/A14.19%65.71%32.73%

Palvella Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PVLA
Palvella Therapeutics
1.6401 of 5 stars
$71.30
-2.8%
$75.50
+5.9%
N/A$810.90M$42.81M0.00N/AShort Interest ↑
QURE
uniQure
2.6033 of 5 stars
$62.83
+6.6%
$71.75
+14.2%
+800.9%$3.23B$27.12M-16.03500
GMTX
Gemini Therapeutics
N/A$73.00
+1.4%
N/A+69.2%$3.16BN/A-73.0030
XENE
Xenon Pharmaceuticals
2.7067 of 5 stars
$41.90
+3.3%
$53.67
+28.1%
-1.3%$3.13B$7.50M-11.80210
SRRK
Scholar Rock
4.4218 of 5 stars
$32.40
+1.6%
$48.60
+50.0%
-2.0%$3.07B$33.19M-11.13140Analyst Forecast
Gap Down
RARE
Ultragenyx Pharmaceutical
4.3238 of 5 stars
$33.43
+5.5%
$81.50
+143.8%
-39.5%$3.05B$610.16M-6.051,294Analyst Forecast
Gap Up
AMRX
Amneal Pharmaceuticals
2.566 of 5 stars
$9.78
+0.6%
$12.00
+22.7%
+22.7%$3.05B$2.85B978.988,100
IMVT
Immunovant
2.2687 of 5 stars
$17.93
+2.5%
$28.78
+60.5%
-36.1%$3.05BN/A-6.29120
CNTA
Centessa Pharmaceuticals
3.6075 of 5 stars
$22.57
+0.7%
$32.38
+43.4%
+50.6%$3.00B$6.85M-12.61200
TARS
Tarsus Pharmaceuticals
1.5324 of 5 stars
$74.95
+7.3%
$66.67
-11.1%
+80.8%$2.95B$182.95M-32.1750Analyst Forecast
Analyst Revision
APLS
Apellis Pharmaceuticals
4.0481 of 5 stars
$25.22
+8.9%
$33.47
+32.7%
+2.0%$2.92B$781.37M-13.86770Upcoming Earnings
Analyst Forecast
Insider Trade

Related Companies and Tools


This page (NASDAQ:PVLA) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners